JP2005529587A - Ｃｄ２００レセプターを調節する方法 - Google Patents

Ｃｄ２００レセプターを調節する方法 Download PDF

Info

Publication number
JP2005529587A
JP2005529587A JP2003576000A JP2003576000A JP2005529587A JP 2005529587 A JP2005529587 A JP 2005529587A JP 2003576000 A JP2003576000 A JP 2003576000A JP 2003576000 A JP2003576000 A JP 2003576000A JP 2005529587 A JP2005529587 A JP 2005529587A
Authority
JP
Japan
Prior art keywords
seq
antibody
cd200ra
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529587A5 (https=
Inventor
ホリー エム． チェルウィンスキ，
ジョセフ エイチ． フィリップス，
ジョナソン ディー． セドグウィック，
マイケル イー． ビグラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005529587A publication Critical patent/JP2005529587A/ja
Publication of JP2005529587A5 publication Critical patent/JP2005529587A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
JP2003576000A 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法 Pending JP2005529587A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36451302P 2002-03-15 2002-03-15
PCT/US2003/007647 WO2003077947A1 (en) 2002-03-15 2003-03-13 Methods of modulating cd200 receptors

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2006058745A Division JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134635A Division JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134634A Division JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Publications (2)

Publication Number Publication Date
JP2005529587A true JP2005529587A (ja) 2005-10-06
JP2005529587A5 JP2005529587A5 (https=) 2006-04-20

Family

ID=28041929

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003576000A Pending JP2005529587A (ja) 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Country Status (16)

Country Link
US (3) US20030223991A1 (https=)
EP (3) EP2100617A1 (https=)
JP (4) JP2005529587A (https=)
AT (1) ATE439861T1 (https=)
AU (3) AU2003220219A1 (https=)
CA (1) CA2478803A1 (https=)
CY (1) CY1109521T1 (https=)
DE (1) DE60328870D1 (https=)
DK (1) DK1482973T3 (https=)
ES (1) ES2330211T3 (https=)
MX (1) MXPA04008937A (https=)
NZ (2) NZ570998A (https=)
PT (1) PT1482973E (https=)
SI (1) SI1482973T1 (https=)
WO (1) WO2003077947A1 (https=)
ZA (2) ZA200407384B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006206598A (ja) * 2002-03-15 2006-08-10 Schering Plough Corp Ｃｄ２００レセプターを調節する方法
JP2010512791A (ja) * 2006-12-22 2010-04-30 シェーリング コーポレイション Ｃｄ２００ｒに対する抗体
JP2010515751A (ja) * 2007-01-11 2010-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ２００およびそのレセプターｃｄ２００ｒは破骨細胞の分化を介して骨質量を調節する

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515382A (en) * 1999-05-13 2004-03-26 Medical Res Council OX2 receptor homologs
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
WO2003103709A2 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Modulation of bone development
MXPA05006978A (es) * 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
JP4919453B2 (ja) * 2005-04-07 2012-04-18 独立行政法人理化学研究所 炎症性疾患の予防又は治療剤
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2010135183A1 (en) * 2009-05-20 2010-11-25 Schering Corporation Modulation of pilr receptors to treat sepsis
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
DK3421486T5 (da) * 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
JP5854432B2 (ja) * 2012-09-28 2016-02-09 森永乳業株式会社 アレルギー反応検出法
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
AR116668A1 (es) * 2018-09-14 2021-06-02 Lilly Co Eli Anticuerpos agonistas contra cd200r y sus usos

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04244028A (ja) * 1990-08-02 1992-09-01 F Hoffmann La Roche Ag 抗アレルギー剤組成物
JPH10212242A (ja) * 1996-11-27 1998-08-11 Tosoh Corp 新規血小板増多剤
JPH11246435A (ja) * 1997-10-29 1999-09-14 Ajinomoto Co Inc 免疫調整剤
WO2000070045A1 (en) * 1999-05-13 2000-11-23 Medical Research Council Ox2 receptor homologs
JP2001515918A (ja) * 1997-09-11 2001-09-25 ネオルックス コーポレイション ケモカインペプチド類、その変異体、誘導体および類似体ならびに炎症応答を阻害または増大する方法へのそれらの使用
JP2006206598A (ja) * 2002-03-15 2006-08-10 Schering Plough Corp Ｃｄ２００レセプターを調節する方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5202267A (en) 1988-04-04 1993-04-13 Hygeia Sciences, Inc. Sol capture immunoassay kit and procedure
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6306608B1 (en) 1996-05-27 2001-10-23 Medical & Biological Laboratories Co., Ltd. Anti-human LECT2 antibody, cells producing the same, and method and kit for assaying the same
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US5948627A (en) 1997-05-30 1999-09-07 One Lambda Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
AU5134799A (en) * 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
WO2002088164A1 (en) 2001-04-26 2002-11-07 Immunex Corporation Human ox2 receptors
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
US20040126777A1 (en) * 2002-01-28 2004-07-01 Bhatt Ramesh Rajani Lp mammalian proteins; related reagents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04244028A (ja) * 1990-08-02 1992-09-01 F Hoffmann La Roche Ag 抗アレルギー剤組成物
JPH10212242A (ja) * 1996-11-27 1998-08-11 Tosoh Corp 新規血小板増多剤
JP2001515918A (ja) * 1997-09-11 2001-09-25 ネオルックス コーポレイション ケモカインペプチド類、その変異体、誘導体および類似体ならびに炎症応答を阻害または増大する方法へのそれらの使用
JPH11246435A (ja) * 1997-10-29 1999-09-14 Ajinomoto Co Inc 免疫調整剤
WO2000070045A1 (en) * 1999-05-13 2000-11-23 Medical Research Council Ox2 receptor homologs
JP2006206598A (ja) * 2002-03-15 2006-08-10 Schering Plough Corp Ｃｄ２００レセプターを調節する方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006206598A (ja) * 2002-03-15 2006-08-10 Schering Plough Corp Ｃｄ２００レセプターを調節する方法
JP2010512791A (ja) * 2006-12-22 2010-04-30 シェーリング コーポレイション Ｃｄ２００ｒに対する抗体
JP2010515751A (ja) * 2007-01-11 2010-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ２００およびそのレセプターｃｄ２００ｒは破骨細胞の分化を介して骨質量を調節する

Also Published As

Publication number Publication date
CA2478803A1 (en) 2003-09-25
AU2007202938A1 (en) 2007-07-19
ZA200407384B (en) 2010-05-26
EP2100617A1 (en) 2009-09-16
NZ553470A (en) 2008-10-31
NZ570998A (en) 2010-08-27
EP1482973B1 (en) 2009-08-19
CY1109521T1 (el) 2014-08-13
MXPA04008937A (es) 2005-06-17
US8263070B2 (en) 2012-09-11
DK1482973T3 (da) 2009-12-07
DE60328870D1 (de) 2009-10-01
US20030223991A1 (en) 2003-12-04
EP1482973A1 (en) 2004-12-08
ATE439861T1 (de) 2009-09-15
ES2330211T3 (es) 2009-12-07
PT1482973E (pt) 2009-11-20
JP2011178813A (ja) 2011-09-15
JP2006206598A (ja) 2006-08-10
SI1482973T1 (sl) 2010-01-29
US20060240010A1 (en) 2006-10-26
ZA201001595B (en) 2012-11-28
US20080166353A1 (en) 2008-07-10
AU2007202938B2 (en) 2011-01-20
AU2011201824A1 (en) 2011-05-19
AU2003220219A1 (en) 2003-09-29
EP2322218A1 (en) 2011-05-18
EP1482973A4 (en) 2006-03-08
JP2011178812A (ja) 2011-09-15
WO2003077947A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
US8263070B2 (en) Methods of modulating CD200 receptors
AU2022203914B2 (en) Methods for inhibiting fibrosis in a subject in need thereof
CN101720232B (zh) 具有修饰的效应器功能的fc受体结合型多肽
KR101024758B1 (ko) 인간 항-ｂ7ｒｐ1 중화 항체
CN103906766B (zh) 抗cd83激动剂抗体用于治疗自身免疫疾病的用途
JP2024026724A (ja) 抗ｃｘｃｒ２抗体及びその使用
CA2836373A1 (en) Mcam antagonists and methods of treatment
EA039807B1 (ru) Антитело к -синуклеину и его применение
JP2021152044A (ja) 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法
US20240239907A1 (en) C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
JP2021521121A (ja) 自己免疫疾患を処置するための方法
AU2020363993B2 (en) Compositions and methods for treating cytotoxic T cell resistant tumors
US20050142108A1 (en) Methods of modulating cytokine activity; related reagents
WO2025171401A2 (en) Antibodies against cd99 and methods of use thereof
WO2025137574A1 (en) Methods for treatment of cancer with polynucleotides or antibodies that target mutated cell surface related proteins
US9296824B2 (en) Methods for treating and preventing multiple sclerosis
Aslanian Targeting of activated macrophages through CD64 to elucidate their role in the pathogenesis of Multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091028

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110315

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111020